RDHL

Business Context and Reporting Period

RedHill Biopharma Ltd. (Nasdaq: RDHL) filed a Form 6-K on April 10, 2025, incorporating a press release detailing full-year 2024 financial results and operational highlights. The company is a specialty biopharmaceutical firm focused on gastrointestinal diseases, infectious diseases, and oncology. The reporting period covers the 12 months ended December 31, 2024.

Key Financial Metrics

Margin Analysis: Gross margin improved to approximately 61% in 2024 compared to 47% in 2023, driven by lower inventory write-downs ($0.2 million in 2024 vs. $1.3 million in 2023). The company reported a capital deficiency of $4.7 million as of December 31, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 23% year-over-year to $8.0 million. Talicia revenues rose to $9.0 million, aided by $1.0 million from a UAE partnership. Movantik contra-revenues decreased to $0.9 million from $2.6 million.
• Expense Reduction: Operating expenses were significantly reduced. R&D expenses dropped 55% to $1.6 million. Selling, Marketing, and G&A expenses fell 50% to $15.5 million, largely due to the 2023 Movantik divestiture and workforce downsizing.
• Profitability Shift: The company swung from a Net Income of $23.9 million in 2023 to a Net Loss of $8.3 million in 2024. The 2023 income was heavily influenced by a $44.1 million gain from the Movantik divestiture and a $20.6 million gain from debt extinguishment. Excluding these one-time items, core operating performance improved due to cost-cutting.
• Cash Flow Efficiency: Cash burn from operations decreased by 74% year-over-year, dropping from $35.8 million to $9.4 million.

Guidance, Outlook, and Operational Highlights

Commercial Pipeline:

• Talicia: Listed as a first-line therapy in the 2024 ACG Clinical Guideline. Secured formulary wins covering 25 million lives. Launched in the UAE with a planned UK Marketing Authorisation Application (MAA) in 2025.
• RHB-102: Secured a global licensing deal (excluding North America) with Hyloris Pharmaceuticals for up to $60 million in potential milestone payments.

R&D Pipeline:

• Opaganib: Initiated a Bayer-supported Phase 2 combination study with darolutamide for prostate cancer. Positive results confirmed in U.S. Government-funded GI-ARS studies. Ongoing work in Ebola and diabetes/obesity indications.
• RHB-204: Advancing into a Phase 2 study for Crohn's Disease (MAP-positive patients), building on RHB-104's positive Phase 3 data. FDA guidance on the approval path is expected soon.
• RHB-107 (Upamostat): U.S. Government funding for the Phase 2 COVID-19 outpatient trial was terminated in January 2025, requiring enrollment to cease on February 28, 2025. Only 93 of 300 target patients were enrolled.

Legal and Contingencies:

• Won a summary judgment against Kukbo in NY Supreme Court for approximately $8 million plus legal costs; collection efforts are ongoing.
• Incurred a $2.3 million loss in 2024 related to the Global Termination Agreement regarding Movantik.

Risks: The filing highlights risks regarding the ability to maintain Nasdaq listing compliance, uncertainty in U.S. government R&D funding, and the potential failure of clinical trials or regulatory approvals.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $4.8 million cash balance against the $9.4 million annual operating cash burn and upcoming R&D funding needs.
• Legal Collection: Monitor the status of the $8 million+ judgment against Kukbo and the likelihood of actual collection.
• Government Funding: Assess the risk of further U.S. government funding cuts, following the termination of the RHB-107 COVID-19 trial funding.
• Regulatory Pathways: Track the anticipated FDA guidance for RHB-204 and the timeline for the UK MAA for Talicia.
• Capital Structure: Review the increase in derivative financial instrument liabilities ($1.4 million) and the capital deficiency position.